Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma

BACKGROUND: Tivantinib has been described as a highly selective inhibitor of MET and is currently in a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC). However, the mechanism of tivantinib anti-tumor effect has been questioned by recent studies. RESULTS: We show that tiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Qingfeng, Zhen, Zuojun, Deng, David YB, Wang, Jingnan, Chen, Yingjun, Li, Jieyuan, Zhang, Yingfei, Wang, Fengjie, Chen, Ningning, Chen, Huanwei, Chen, Yajin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603939/
https://www.ncbi.nlm.nih.gov/pubmed/26458953
http://dx.doi.org/10.1186/s13046-015-0238-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603939/
https://www.ncbi.nlm.nih.gov/pubmed/26458953
http://dx.doi.org/10.1186/s13046-015-0238-2

Ejemplares similares